The Congress should require the Secretary to:
- reduce add-on payments for costly Part B drugs and biologics paid based on average sales price in order to minimize the relationship between average sales price and add-on payments, and
- eliminate add-on payments for Part B drugs and biologics paid based on wholesale acquisition cost.